Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4727-4732

  Todorova, K ^a   Zoubak, S ^b   Mincheff, M ^b,c   Kyurkchiev, Stanimir ^a  

^a BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c National Center of Hematology and Transfusion Medicine   (Bulgaria)

Author keywords

Anti PSMA antibodies; Carbohydrate cleaving enzyme; Gene based PSMA vaccination; LNCaP cells; Prostate cancer; Proteases

Indexed keywords

BETA GLUCURONIDASE; CANCER VACCINE; EPITOPE; FRUCTOSIDASE; GALACTOSIDASE; GLUCOSE OXIDASE; GLYCOPEPTIDASE F; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPSIN A; PLASMID DNA; PRONASE E; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN PLASMID DNA; PROTEINASE; PROTEINASE K; RECOMBINANT PROTEIN; SUBTILISIN; TRYPSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BIOCHEMISTRY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRAL GENE THERAPY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; ANTIGENS, SURFACE; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; EPITOPE MAPPING; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; VACCINES, DNA;

EID: 28444454429     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Murphy GP, Elgamal AA, Su SL, Bostwick DG and Holmes EH: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83: 2259-2269, 1998.
2. Horoszewicz JS, Kawinski E and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-935, 1987.
3. Israeli RS, Powell CT, Fair WR and Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230, 1993.
4. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT and Heston WD: Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30: 105-108, 1995.
5. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ and Gilman SC: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50: 6423-6429, 1990.
6. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
7. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ et al: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306-6310, 1994.
8. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5: 2674-2681, 1999.
9. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198, 1999.
10. Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S and Mincheff M: Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 5: 1, 2005.
11. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S and Meryman HT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 38: 208-217, 2000.
12. Mincheff M, Altankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva E, Kurteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, Lissitchkov T, Chernozemski I and Meryman HT: In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer - changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 39: 125-132, 2001.
13. Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS and Konvalinka J: Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 80: 477-487, 2002.
14. Kesmir C, Nussbaum AK, Schild H, Detours V and Brunak S: Prediction of proteasome cleavage motifs by neural networks. Protein Eng 15: 287-296, 2002.
15. Mincheff M, Zoubak S, Altankova I, Tchakarov S, Makogonenko Y, Botev C, Ignatova I, Dimitrov R, Madarzhieva K, Hammett M, Pomakov Y, Meryman H and Lissitchkov T: Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther 10: 907-917, 2003.
16. Kuratsukuri K, Wang CY, Sone T, Nishisaka N, Jones RF and Haas GP: Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. Eur Urol 42: 67-73, 2002.
17. Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE and Pachuk CJ: Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 182: 1311-1320, 2000.
18. Pilon SA, Piechocki MP and Wei WZ: Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167: 3201-3206, 2001.